arrow
G

Guillaume Martel

University of Ottawa
H指数:46
被引数:7,726

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Risk- adjusted Cumulative Sum (RA-CUSUM) method for real time monitoring of surgical units performance.

风险调整的累积和(RA-CUSUM)方法用于外科单元绩效的实时监测

HPB
IF2.4
2026-05-060
PRE
Surgical and Procedural Bleed Risk Stratification for Anticoagulated Patients Undergoing Planned Surgery: Guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis
2026-02-050
PRE
Perioperative Changes in ALBI and Platelets (CAP): Association with Postoperative Complications Among Patients Undergoing Surgery for Hepatocellular Carcinoma

围手术期ALBI和血小板变化(CAP):与肝细胞癌手术患者术后并发症的关联

HPB
IF2.4
2025-12-040
PRE
Beyond the Composite: Differential Impact of Albumin and Bilirubin Relative to Tumor Burden in HCC

超越综合指标:白蛋白和胆红素相对于肝癌肿瘤负荷的差异化影响

2025-11-260
PRE
ASO Visual Abstract: Preoperative Systemic Immune-Inflammatory Index Predicts Occult Nodal Disease in Clinically Node-Negative Intrahepatic Cholangiocarcinoma

ASO视觉摘要:术前系统性免疫炎症指数预测临床淋巴结阴性的肝内胆管癌的隐匿性淋巴结疾病

2025-08-230
PRE
An easy-to-use online calculator to identify patients least likely to benefit from surgical resection of intrahepatic cholangiocarcinoma

一个易于使用的在线计算器,用于识别从肝内胆管癌手术切除中获益可能性最小的患者

Surgery
IF2.7
2025-07-140
PRE
Perioperative dynamic changes of systemic inflammatory biomarkers predict tumor recurrence following curative-intent resection of hepatocellular carcinoma

肝细胞癌根治性切除术后肿瘤复发的预测:全身炎症生物标志物的围手术期动态变化

2025-07-090
PRE
Preoperative Systemic Immune-Inflammatory Index Predicts Occult Nodal Disease in Clinically Node-Negative Intrahepatic Cholangiocarcinoma

术前系统性免疫炎症指数可预测临床淋巴结阴性肝内胆管癌的隐匿性淋巴结转移

2025-07-090
OAAI
Model of End-Stage Liver Disease-alpha-fetoprotein-tumor burden (MELD-AFP-TBS) score to stratify prognosis after liver resection for hepatocellular carcinoma

终末期肝病模型-甲胎蛋白-肿瘤负荷(MELD-AFP-TBS)评分用于肝细胞癌肝切除术后预后分层

SURGERY
IF2.7
2025-07-010
PRE
Development and validation of a preoperative risk prediction model for severe complications and very early recurrence after liver resection for hepatocellular carcinoma

肝细胞癌肝切除术后严重并发症及极早期复发的术前风险预测模型的建立与验证

Surgery
IF2.7
2025-06-280
PRE
Impact of disparity between imaging and pathological tumor size on cancer-specific prognosis among patients with hepatocellular carcinoma
EJSO
IF2.9
2025-06-010
PRE
Safety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): a multicentre, single-arm clinical trial

联合门静脉和肝静脉栓塞术在结直肠癌肝转移患者中的安全性与有效性(DRAGON1):一项多中心、单臂临床试验

2025-06-010
PRE
Unraveling the obesity paradox in hepatocellular carcinoma: relative role of elevated body mass index on detrimental effects of postoperative complications

解析肝细胞癌中的肥胖悖论:升高体重指数对术后并发症有害影响的相对作用

HPB
IF2.4
2025-05-280
PRE
ASO Visual Abstract: Recurrence-Free Survival as a Surrogate for Overall Survival among Patients with Intrahepatic Cholangiocarcinoma following Upfront Surgery-An International Multi-Institutional Analysis

ASO可视化摘要:根治术后肝内胆管癌患者的无复发生存率作为总生存率的替代指标——一项国际多中心分析

2025-05-190
PRE
Up-front resection for hepatocellular carcinoma: Assessing futility in the preoperative setting
EJSO
IF2.9
2025-05-010
PRE
Enhancing Recurrence-Free Survival Prediction in Hepatocellular Carcinoma: A Time-Updated Model Incorporating Tumor Burden and AFP Dynamics
2025-04-011
OAAI